The Population Genetics of Collateral Resistance and Sensitivity

Sarah M. Ardell¹ and Sergey Kryazhimskiy^{1*}

*For correspondence:
skryazhi@ucsd.edu (SK)

¹ Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093

Abstract Resistance mutations against one drug can elicit collateral sensitivity against other drugs. Multi-drug treatments exploiting such trade-offs can help slow down the evolution of resistance. However, if mutations with diverse collateral effects are available, a treated population may evolve either collateral sensitivity or collateral resistance. How to design treatments robust to such uncertainty is unclear. We show that many resistance mutations in *Escherichia coli* against various antibiotics indeed have diverse collateral effects. We propose to characterize such diversity with a joint distribution of fitness effects (JDFE) and develop a theory for describing and predicting collateral evolution based on simple statistics of the JDFE. We show how to robustly rank drug pairs to minimize the risk of collateral resistance and how to estimate JDFEs. In addition to practical applications, these results have implications for our understanding of evolution in variable environments.

Introduction

The spread of resistance against most antibiotics and the difficulties in developing new ones has sparked considerable interest in using drug combinations and sequential drug treatments to treat bacterial infections, as well as cancers (Pál et al., 2015). Treatments where the drugs are chosen so that resistance against one of them causes the pathogen or cancer population to become sensitive to the other—a phenomenon known as collateral sensitivity—can eliminate the population before multi-drug resistance emerges (Pál et al., 2015; Pluchino et al., 2012).

The success of a multi-drug treatment hinges on knowing which drugs select for collateral sensitivity against which other drugs. This information is obtained empirically by exposing bacterial and cancer-cell populations to drugs and observing the evolutionary outcomes (Roemhild et al., 2020; Jensen et al., 1997; Imamovic and Sommer, 2013; Lázár et al., 2018; Maltas and Wood, 2019; Batra et al., 2021; Sanz-García et al., 2020; Schenk et al., 2015; Lázár et al., 2013; Barbosa et al., 2019; Hernando-Amado et al., 2020; Kim et al., 2014; Jahn et al., 2021; Kavanaugh et al., 2020; Laborda et al., 2021; Oz et al., 2014; Munck et al., 2014). Prior studies have largely focused on various empirical questions related to the evolution of collateral sensitivity and resistance, such as identifying their genetic basis (Lázár et al., 2014; Roemhild et al., 2020; Maltas and Wood, 2019; Hernando-Amado et al., 2020; Kavanaugh et al., 2020; Laborda et al., 2021), understanding how collateral outcomes depend on treatment design (e.g. sequential versus combination) (Lázár et al., 2014; Munck et al., 2014; Bergstrom et al., 2004; Batra et al., 2021; Sanz-García et al., 2020; Schenk et al., 2015; Lázár et al., 2013; Kim et al., 2014; Jahn et al., 2021), or testing whether collateral sensitivity is an evolutionarily stable outcome (Barbosa et al., 2019). However, one important feature of these experimental studies has received little attention, namely, the fact that different experiments often produce collateral sensitivity profiles that are inconsistent with each other (e.g., Imamovic and Sommer, 2013; Oz et al., 2014; Barbosa et al., 2017; Maltas and Wood, 2019). Some inconsistencies can be explained by the fact that resistance mutations vary between bacterial

43 strains, drug dosages, etc. (*Mira et al., 2015; Barbosa et al., 2017; Das et al., 2020; Pinheiro et al.,*
44 *2021; Card et al., 2021; Gjini and Wood, 2021*). However, wide variation in collateral outcomes is
45 observed even between replicate populations (*Oz et al., 2014; Barbosa et al., 2017; Maltas and*
46 *Wood, 2019; Nichol et al., 2019*). This variation suggests that bacteria and cancers have access
47 to multiple resistance mutations with diverse collateral effects and that replicate populations
48 accumulate different resistance mutations due to the intrinsic randomness of the evolutionary
49 process (*Jerison et al., 2020; Nichol et al., 2019*). However, the diversity of collateral effects among
50 resistance mutations has rarely if ever been systematically measured. Moreover, few existing
51 approaches for designing robust multi-drug treatments have modelled this mutational diversity
52 explicitly within the population genetics context (*Nichol et al., 2019; Maltas and Wood, 2019*). Yet,
53 a theory grounded in population genetics could help us understand how the expected collateral
54 outcomes and the uncertainty around these expectations depend on evolutionary parameters and
55 how these expectations and uncertainties change over time.

56 Here we develop such a theory. Collateral sensitivity and resistance are specific examples of
57 the more general evolutionary phenomenon, pleiotropy, which refers to any situation when one
58 mutation affects multiple phenotypes (*Wagner and Zhang, 2011; Paaby and Rockman, 2013*). In
59 case of drug resistance evolution, the direct effect of resistance mutations is to increase fitness in
60 the presence of one drug (the “home” environment). In addition, they may also provide pleiotropic
61 gains or losses in fitness in the presence of other drugs (the “non-home” environments) leading to
62 collateral resistance or sensitivity, respectively.

63 Classical theoretical work on pleiotropy has been done in the field of quantitative genetics (*Lande*
64 *and Arnold, 1983; Rose, 1982; Barton, 1990; Slatkin and Frank, 1990; Jones et al., 2003; Johnson*
65 *and Barton, 2005*). In these models, primarily developed to understand how polygenic traits
66 respond to selection in sexual populations, pleiotropy manifests itself as a correlated temporal
67 change in multiple traits in a given environment. The question of how new strongly beneficial
68 mutations that accumulate in asexual populations evolving in one environment affect its fitness in
69 future environments is outside of the scope of these models.

70 The pleiotropic consequences of adaptation have also been explored in various “fitness land-
71 scape” models (e.g. *Connallon and Clark, 2015; Martin and Lenormand, 2015; Harmand et al., 2017;*
72 *Wang and Dai, 2019; Maltas et al., 2021; Nichol et al., 2019; Tikhonov et al., 2020*). In particular,
73 *Nichol et al. (2019)* specifically addressed the problem of diversity of collateral resistance/sensitivity
74 outcomes in the context of a combinatorially complete fitness landscapes of four mutations in
75 the TEM β -lactamase gene. They found that different *in silico* populations adapting to the same
76 antibiotic often arrive at different fitness peaks which results in different levels of collateral resis-
77 tance/sensitivity against other drugs. They observed qualitatively similar variability in the collateral
78 outcomes among replicate populations of *E. coli* evolving in the presence of cefotaxime (CTX),
79 although it is unclear whether different populations indeed arrived at different fitness peaks. In
80 general, the fitness landscape approach helps us understand how evolutionary trajectories and out-
81 comes depend on the global structure of the underlying fitness landscape. However, applying this
82 approach in practice is challenging because the global structure of fitness landscapes is unknown
83 and notoriously difficult to estimate, even in controlled laboratory conditions.

84 Here, we take a different approach which is agnostic with respect to the global structure of the
85 fitness landscape. Instead, we assume only the knowledge of the so-called joint distribution of
86 fitness effects (JDFE), i.e., the probability that a new mutation has a certain pair of fitness effects in
87 the home and non-home environments (*Jerison et al., 2014; Martin and Lenormand, 2015; Bono*
88 *et al., 2017*). The JDFE is a natural extension of the DFE, the distribution of fitness effects of new
89 mutations, often used in modeling evolution in a single environment (*King, 1972; Ohta, 1987; Orr,*
90 *2003; Rees and Bataillon, 2006; Eyre-Walker and Keightley, 2007; Martin and Lenormand, 2008;*
91 *MacLean and Buckling, 2009; Kryazhimskiy et al., 2009; Levy et al., 2015*). Like the DFE, the JDFE is
92 a local property of the fitness landscape which means that it can be, at least in principle, estimated
93 by using a variety of modern high-throughput techniques (e.g., *Qian et al., 2012; Van Opijnen*

et al., 2009; Chevereau et al., 2015; Levy et al., 2015; Blundell et al., 2019; Aggeli et al., 2021). The downside of this approach is that the JDFE can change over time as the population traverses the fitness landscape (Good et al., 2017; Venkataram et al., 2020; Aggeli et al., 2021). However, in the context of collateral drug resistance and sensitivity, we are primarily interested in short time scales over which the JDFE can be reasonably expected to stay approximately constant.

The rest of the paper is structured as follows. First, we use previously published data to demonstrate that the bacterium *Escherichia coli* has access to drug resistance mutations with diverse collateral effects. This implies that, rather than treating collateral effects as deterministic properties of drug pairs, we should think of them probabilistically, in terms of the respective JDFEs. We then show that a naive intuition about how the JDFE determines pleiotropic outcomes of evolution can sometimes fail, and a mathematical model is therefore required. We develop such a model, which reveals two key “pleiotropy statistics” of the JDFE that determine the dynamics of fitness in the non-home condition. Our theory makes quantitative predictions in a variety of regimes if the population genetic parameters are known. However, we argue that in the case of drug resistance evolution the more important problem is to robustly order drug pairs in terms of their collateral sensitivity profiles even if the population genetic parameters are unknown. We develop a metric that allows us to do so. Finally, we provide some practical guidance for estimating the pleiotropy statistics of empirical JDFEs in the context of ranking drug pairs.

Results

Antibiotic resistance mutations in *E. coli* have diverse collateral effects

We begin by demonstrating that JDFE is a useful concept for modeling the evolution of collateral antibiotic resistance and sensitivity. If all resistance mutations against a given drug had identical pleiotropic effects on the fitness of the organism in presence of another drug, the dynamics of collateral resistance/sensitivity could be understood without the JDFE concept. On the other hand, if different resistance mutations have different pleiotropic fitness effects, predicting the collateral resistance/sensitivity dynamics requires specifying the probabilities with which mutations with various home and non-home fitness effects arise in the population. The JDFE specifies these probabilities. Therefore, for the JDFE concept to be useful in the context of collateral resistance/sensitivity evolution, we need to show that resistance mutations against common drugs have diverse collateral effects in the presence of other drugs.

To our knowledge, no data sets are currently publicly available that would allow us to systematically explore the diversity of collateral effects among all resistance mutations against any one drug in any organism. Instead, we examined the fitness effects of 3883 gene knock-out mutations in the bacterium *Escherichia coli*, measured in the presence of six antibiotics (Chevereau et al., 2015), as well as the fitness effects of 4997 point mutations in the TEM-1 β -lactamase gene measured in the presence of two antibiotics (Stiffler et al., 2015).

For four out of six antibiotics used by Chevereau et al. (2015), we find between 12 (0.31 %) and 170 (4.38 %) knock-out mutations that provide some level of resistance against at least one of the antibiotics (false discovery rate (FDR) $\sim 25\%$; Figure 1, Figure 1–source data 1; see Materials and Methods for details). Plotting on the x -axis the fitness effect of each knock-out mutation in the presence of the drug assumed to be applied first (i.e., the home environment) against its effect in the presence of another drug assumed to be applied later (i.e., the non-home environment, y -axis), we find mutations in all four quadrants of this plane, for all 12 ordered drug pairs (Figure 1, Figure 1–source data 1). Similarly, we find diverse collateral effects among mutations within a single gene (Figure 1–Figure Supplement 1; see Materials and Methods for details).

Since both data sets represent subsets of all resistance mutations, we conclude that *E. coli* likely have access to resistance mutations with diverse pleiotropic effects, such that a fitness gain in the presence of any one drug can come either with a pleiotropic gain or a pleiotropic loss of fitness in the presence of other drugs. Therefore, the JDFE framework is suitable for modeling the evolution

Figure 1. (Previous page) Fitness effects of gene knock-out mutations in *E. coli* in the presence of four antibiotics. Data are from [Chevereau et al. \(2015\)](#). Each diagonal panel shows the distribution of fitness effects (DFE) of knock-out mutations in the presence of the corresponding antibiotic (equivalent to Figure 1C in [Chevereau et al. \(2015\)](#)). Scale of the y-axis in these panels is indicated inside on the right. The estimated measurement noise distributions are shown in red (see Materials and Methods for details). Note that some noise distributions are vertically cut-off for visual convenience. The number of identified beneficial mutations (i.e., resistance mutations) and the expected number of false positives (in parenthesis) are shown in the bottom left corner. The list of identified resistance mutations is given in the **Figure 1-source data 1**. Off-diagonal panels show the fitness effects of knock-out mutations across pairs of drug environments. The x-axis shows the fitness in the environment where selection would happen first (i.e., the “home” environment). Each point corresponds to an individual knock-out mutation. Resistance mutations identified in the home environment are colored according to their collateral effects, as indicated in the legend. The numbers of mutations of each type are shown in the corresponding colors in the bottom left corner of each panel. TET: tetracycline; NIT: nitrofurantoin; MEC: mecillinam; CPR: ciprofloxacin.

Figure 1-Figure supplement 1. JDfEs of single point mutations in TEM-1 β -lactamase gene in *E. coli* in the presence of cefotaxime and ampicillin.

Figure 1-source data 1. *P*-values and calls of collateral effects of beneficial knock-out mutations in the [Chevereau et al. \(2015\)](#) data (see Materials and Methods for details).

Figure 1-source data 2. Calls of collateral effects of mutations beneficial in CTX in the [Stiffler et al. \(2015\)](#) data (see Materials and Methods for details).

of collateral resistance/sensitivity. In the next section, we formally define a JDfE and probe our intuition for how its shape determines the fitness trajectories in the non-home environment.

JDfE determines the pleiotropic outcomes of adaptation

For any genotype g that finds itself in one (“home”) environment and may in the future encounter another “non-home” environment, we define the JDfE as the probability density $\Phi_g(\Delta x, \Delta y)$ that a new mutation that arises in this genotype has the selection coefficient Δx in the home environment and the selection coefficient Δy in the non-home environment ([Jerison et al., 2014](#)). For concreteness, we define the fitness of a genotype as its malthusian parameter ([Crow and Kimura, 1972](#)). So, if the home and non-home fitness of genotype g are x and y , respectively, and if this genotype acquires a mutation with selection coefficients Δx and Δy , its fitness becomes $x + \Delta x$ and $y + \Delta y$. This definition of the JDfE can, of course, be naturally extended to multiple non-home environments. In principle, the JDfE can vary from one genotype to another. However, to develop a basic intuition for how the JDfE determines pleiotropic outcomes, we assume that all genotypes have the same JDfE. We discuss a possible extension to epistatic JDfEs in [Appendix 1](#).

The JDfE is a complex object. So, we first ask whether some simple and intuitive summary statistics of the JDfE may be sufficient to predict the dynamics of the non-home fitness of a population that is adapting in the home environment. Intuitively, if there is a trade-off between home and non-home fitness, non-home fitness should decline; if the opposite is true, non-home fitness should increase. Canonically, a trade-off occurs when any mutation that improves fitness in one environment decreases it in the other environment and vice versa ([Roff and Fairbairn, 2007](#)). Genotypes that experience such “hard” trade-offs are at the Pareto front ([Shoval et al., 2012](#); [Li et al., 2019](#)). For genotypes that are not at the Pareto front, some mutations that are beneficial in the home environment may be beneficial in the non-home environment and others may be deleterious. In this more general case, trade-offs are commonly quantified by the degree of negative correlation between the effects of mutations on fitness in the two environments ([Roff and Fairbairn, 2007](#); [Tikhonov et al., 2020](#)). Thus, we might expect that evolution on negatively correlated JDfEs would lead to pleiotropic fitness losses and evolution on positively correlated JDfEs would lead to pleiotropic fitness gains.

To test this intuition, we generated a family of Gaussian JDfEs that varied, among other things, by their correlation structure ([Figure 2](#); Materials and Methods). We then simulated the evolution of an asexual population on these JDfEs using a standard Wright-Fisher model (Materials and

Figure 2. Gaussian JDFEs and the resulting fitness trajectories. **A-E.** Contour lines for five Gaussian JDFEs. “x” marks the mean. For all distributions, the standard deviation is 0.1 in both home- and non-home environments. The correlation coefficient ρ is shown in each panel. **F-J.** Home and non-home fitness trajectories for the JDFEs shown in the corresponding panels above. Thick lines show the mean, ribbons show ± 1 standard deviation estimated from 100 replicate simulations. Population size $N = 10^4$, mutation rate $U = 10^{-4}$ ($U_b = 4.6 \times 10^{-5}$).

Figure 2-Figure supplement 1. JDFEs with equal probability weights in the first and fourth quadrants and the resulting fitness trajectories. See Materials and Methods for details.

Methods) and tested whether the trade-off strength, measured by the JDFE's correlation coefficient, predicts the dynamics of non-home fitness. **Figure 2** shows that our naive expectation is incorrect. Positively correlated JDFEs sometimes lead to pleiotropic fitness losses (**Figure 2D,I**), and negatively correlated JDFEs sometimes lead to pleiotropic fitness gains (**Figure 2B,G**). Even if we calculate the correlation coefficient only among mutations that are beneficial in the home environment, the pleiotropic outcomes still do not always conform to the naive expectation, as the sign of the correlation remains the same as for the full JDFEs in all these examples.

There are other properties of the JDFE that we might intuitively expect to be predictive of the pleiotropic outcomes of adaptation. For example, among the JDFEs considered in **Figure 2**, it is apparent that those with similar relative probability weights in the first and fourth quadrants produce similar pleiotropic outcomes. However, simulations with other JDFE shapes show that even distributions that are similar according to this metric can also result in qualitatively different pleiotropic outcomes (**Figure 2-Figure Supplement 1**).

Overall, our simulations show that JDFEs with apparently similar shapes can produce qualitatively different trajectories of pleiotropic fitness changes (e.g., compare **Figure 2A,F** and **Figure 2B,G** or **Figure 2D,I** and **Figure 2E,J**). Conversely, JDFEs with apparently different shapes can result in rather similar pleiotropic outcomes (e.g., compare **Figure 2B,G** and **Figure 2E,J** or **Figure 2A,F** and **Figure 2D,I**). Thus, while the overall shape of the JDFE clearly determines the trajectory of pleiotropic fitness changes, it is not immediately obvious what features of its shape play the most important role, particularly if the JDFE is more complex than a multivariate Gaussian. In other words, even if we have perfect knowledge of the fitness effects of all mutations in multiple environments, converting this knowledge into a qualitative prediction of the expected direction of pleiotropic fitness change

(gain or loss) does not appear straightforward. Therefore, we next turn to developing a population genetics model that would allow us to predict not only the direction of pleiotropic fitness change but also the expected rate of this change and the uncertainty around the expectation.

The population genetics of pleiotropy

To systematically investigate which properties of the JDFE determine the pleiotropic fitness changes in the non-home environment, we consider a population of size N that evolves on a JDFE in the “strong selection weak mutation” (SSWM) regime, also known as the “successional mutation” regime (Orr, 2000; Desai and Fisher, 2007; Kryazhimskiy et al., 2009; Good and Desai, 2015).

We consider an arbitrary JDFE without epistasis, that is a situation when all genotypes have the same JDFE $\Phi(\Delta x, \Delta y)$. We explore an extension to JDFEs with a simple form of epistasis in **Appendix 1**. We assume that mutations arise at rate U per individual per generation. In the SSWM limit, a mutation that arises in the population either instantaneously fixes or instantaneously dies out. Therefore, the population is essentially monomorphic at all times, such that at any time t we can characterize it by its current pair of fitness values (X_t, Y_t) . If a new mutation with a pair of selection coefficients $(\Delta x, \Delta y)$ arises in the population at time t , it fixes with probability $\pi(\Delta x) = \frac{1-e^{-2\Delta x}}{1-e^{-2N\Delta x}}$ (Kimura, 1962) in which case the population’s fitness transitions to a new pair of values $(X_t + \Delta x, Y_t + \Delta y)$. If the mutation dies out, an event that occurs with probability $1 - \pi(\Delta x)$, the population’s fitness does not change. This model specifies a continuous-time two-dimensional Markov process.

In general, the dynamics of the probability density $p(x, y, t)$ of observing the random vector (X_t, Y_t) at values (x, y) are governed by an integro-differential forward Kolmogorov equation, which is difficult to solve (Materials and Methods). However, if most mutations that contribute to adaptation have small effects, these dynamics are well approximated by a diffusion equation which can be solved exactly (Materials and Methods). Then $p(x, y, t)$ is a normal distribution with mean vector

$$\mathbf{m}(t) = \begin{pmatrix} x_0 \\ y_0 \end{pmatrix} + \begin{pmatrix} r_1 \\ r_2 \end{pmatrix} NU_b t \quad (1)$$

and variance-covariance matrix

$$\sigma^2(t) = \begin{pmatrix} D_{11} & D_{12} \\ D_{12} & D_{22} \end{pmatrix} NU_b t, \quad (2)$$

where r_1 and r_2 , given by **Equation 7** and **Equation 8** in Materials and Methods, are the expected fitness effects in the home and non-home environments for a mutation fixed in the home environment, and D_{11} , D_{12} and D_{22} , given by **Equation 9–Equation 11** in Materials and Methods, are the second moments of this distribution. Here, $U_b = U \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \Phi(\xi, \eta)$ is the total rate of mutations beneficial in the home environment, and x_0 and y_0 are the initial values of population’s fitness in the home and non-home environments.

Equation 1 and **Equation 2** show that the distribution of population’s fitness at time t in the non-home environment is entirely determined by two parameters, r_2 and D_{22} , which we call the pleiotropy statistics of the JDFE. The expected rate of fitness change in the non-home environment depends on the pleiotropy statistic r_2 , which we refer to as the expected pleiotropic effect. Thus, evolution on a JDFE with a positive r_2 is expected to result in pleiotropic fitness gains and evolution on a JDFE with a negative r_2 is expected to result in pleiotropic fitness losses. **Equation 2** shows that the variance around this expectation is determined by the pleiotropy variance statistic D_{22} . Since both the expectation and the variance change linearly with time (provided $r_2 \neq 0$), the change in the non-home fitness in any replicate population will eventually have the same sign as r_2 , but the time scale of such convergence depends on the “collateral resistance risk” statistic $c = r_2 / \sqrt{D_{22}}$ (Materials and Methods). This observation has important practical implications, and we return to it in the Section “Robust ranking of drug pairs”.

Figure 3. Pleiotropy statistics predict the properties of non-home fitness trajectories in simulations. Each point corresponds to an ensemble of replicate simulation runs with the same population genetic parameters on one of 125 Gaussian JDFEs (see [Figure 3-source data 1](#) for the JDFE parameters). **A.** Expected pleiotropic effect r_2 versus the scaled slope of the mean rate of non-home fitness change observed in SSWM simulations. **B.** Pleiotropic variance D_{22} versus the scaled rate of change in the variance in non-home fitness observed in SSWM simulations. **C, E, G.** Expected pleiotropic effect r_2^* versus the scaled slope of the mean rate of non-home fitness change observed in Wright-Fisher simulations. **D, F, H.** Pleiotropic variance D_{22}^* versus the scaled rate of change in the variance in non-home fitness observed in Wright-Fisher simulations. (See [Figure 3-Figure Supplement 1](#) for comparison between simulations and the unadjusted pleiotropy statistics r_2 and D_{22} .) 1000 replicate simulations were carried out in the SSWM regime. All Wright-Fisher simulations were carried out with $U = 10^{-4}$ and variable N , 300 replicate simulations per data point (see Materials and Methods for details). In all panels, the grey dashed line represents the identity (slope 1) line, and the solid line of the same color as the points is the linear regression for the displayed points (R^2 value is shown in each panel; $P < 2 \times 10^{-16}$ for all regressions).

Figure 3-Figure supplement 1. Same as [Figure 3C-H](#), but with r_2 and D_{22} shown on the x-axis.

Figure 3-source data 1. Parameters and summary statistics of simulation results for all Gaussian JDFEs used in [Figure 3](#).

239 These theoretical results suggest a simple explanation for the somewhat counter-intuitive
 240 observations in **Figure 2**. We may intuitively believe that evolution on negatively correlated JDFEs
 241 should lead to fitness losses in the non-home environment because on such JDFEs mutations
 242 with largest fitness benefits in the home environment typically have negative pleiotropic effects.
 243 However, such mutations may be too rare to drive adaptation. At the same time, the more common
 244 mutations that do typically drive adaptation may have positive pleiotropic effects, in which case
 245 the population would on average gain non-home fitness, as in **Figure 2B**. Our theory shows that
 246 to predict the direction of non-home fitness change the frequency of beneficial mutations with
 247 various pleiotropic effects and the strength of these effects need to be weighted by the likelihood
 248 that these mutations fix. The expected pleiotropic effect r_2 accomplishes this weighting.

249 We tested the validity of equations **Equation 1** and **Equation 2** by simulating evolution in the
 250 SSWM regime on 125 Gaussian JDFEs with various parameters (Materials and Methods) and found
 251 excellent agreement (**Figure 3A,B**). However, many microbes likely evolve in the “concurrent muta-
 252 tion” regime, i.e., when multiple beneficial mutations segregate in the population simultaneously
 253 (Desai and Fisher, 2007; Lang et al., 2013). As expected, our theory fails to quantitatively predict
 254 the pleiotropic fitness trajectories when $NU_b > 1$ (**Figure 3–Figure Supplement 1**). However, the
 255 expected rate of change of non-home fitness and its variances remain surprisingly well correlated
 256 with the pleiotropy statistics r_2 and D_{22} across various JDFEs (**Figure 3–Figure Supplement 1**). In
 257 other words, we can still use these statistics to correctly predict whether a population would lose or
 258 gain fitness in the non-home environment and to order the non-home environments according to
 259 their expected pleiotropic fitness changes and variances. We will exploit the utility of such ranking
 260 in the next section.

261 We next sought to expand our theory to the concurrent mutation regime. A key characteristic of
 262 adaptation in this regime is that mutations whose fitness benefits in the home environment are
 263 below a certain “effective neutrality” threshold are usually outcompeted by superior mutations and
 264 therefore fix with lower probabilities than predicted by Kimura’s formula (Schiffels et al., 2011; Good
 265 et al., 2012). Good et al. (2012) provide an equation for calculating the fixation probability $\pi^*(\Delta x)$
 266 for a mutation with home fitness benefit Δx in the concurrent mutation regime (equation (6) in
 267 Good et al. (2012)). Thus, by replacing 2ξ (the approximate fixation probability in the SSWM regime)
 268 in **Equation 8** and **Equation 11** with $\pi^*(\xi)$, we obtain the adjusted pleiotropy statistics r_2^* and D_{22}^*
 269 for the concurrent mutation regime (see Materials and Methods for details). Note that in contrast to r_2
 270 and D_{22} , the adjusted statistics r_2^* and D_{22}^* depend on the population genetic parameters N and U_b .

271 To test how well these statistics predict the dynamics of fitness in the non-home environment,
 272 we simulated evolution on the same 125 JDFEs using the full Wright-Fisher model with a range of
 273 population genetic parameters that span the transition from the successional to the concurrent
 274 mutation regimes for 1000 generations. We find that r_2^* quantitatively predicts the expected rate of
 275 non-home fitness change, with a similar accuracy as Good et al. (2012) predict the rate of fitness
 276 change in the home environment, as long as $NU_b > 1$ (**Figure 3C,E,G**; compare with **Figure 3–**
 277 **Figure Supplement 1A,C,E**). D_{22}^* also predicts the empirically observed variance in non-home fitness
 278 trajectories much better than D_{22} , although this relationship is more noisy than between mean
 279 fitness and r_2^* (**Figure 3D,F,H**; compare with **Figure 3–Figure Supplement 1B,D,F**). Some of this noise
 280 can be attributed to sampling, as we estimate both the mean and the variance from 300 replicate
 281 simulation runs, and the variance estimation is more noisy. Even in the absence of sampling noise
 282 however, we do not expect that D_{22}^* would predict the non-home fitness variance perfectly because
 283 our theory does not account for the autocorrelation in the fitness trajectories that arise in the
 284 concurrent mutation regime but not in the successive mutation regime (see Appendix D in Desai
 285 and Fisher (2007)). To our knowledge, a rigorous analytical calculation for ensemble variance in
 286 fitness even in the home environment is not yet available.

287 Overall, our theory allows us to quantitatively predict the dynamics of non-home fitness in a
 288 range of evolutionary regimes if the JDFE and the population genetic parameters N and U_b are
 289 known. However, neither the full JDFE nor the population genetic parameters will likely be known

in most practical situations, such as designing a drug treatment for a cancer patient. In the next section, we address the question of how to robustly select drug pairs for a sequential treatment, assuming that the pleiotropy statistics r_2 and D_{22} are known but the population genetic parameters are not. In the Section “Measuring JDFEs” we provide some guidance on how the JDFE can be measured.

Figure 4. Robust ranking of drug pairs. **A.** Four hypothetical JDFEs, ranked by their c statistic. For all four JDFEs, the mean and the standard deviation in the home environment are -1×10^{-3} and 0.01 , respectively. The mean and the standard deviation in the non-home environment are 1×10^{-4} and 5.1×10^{-3} (rank 1), 2.6×10^{-3} and 7.5×10^{-3} (rank 2), 5.1×10^{-3} and 7.5×10^{-3} (rank 3), 7.5×10^{-3} and 0.01 (rank 4). Correlation coefficient for all four JDFEs is -0.9 . **B.** Collateral resistance risk over time, measured as the fraction of populations with positive mean fitness in the non-home environment. These fractions are estimated from 1000 replicate Wright-Fisher simulation runs with $N = 10^4$, $U = 10^{-4}$ ($NU_b = 0.46$). Colors correspond to the JDFEs in panel A. Numbers indicate the c -rank of each JDFE. **C.** A priori c -rank (x-axis) versus the a posteriori rank (y-axis) based on the risk of collateral resistance observed in simulations, for all 125 Gaussian JDFEs and all NU_b values shown in Figure 3. Grey dashed line is the identity line. R^2 values are 0.94, 0.81 and 0.82 for $NU_b = 0.46, 4.6$ and 46 , respectively. $P < 10^{-15}$ for all regressions.

Figure 4-Figure supplement 1. Ranking of AMP concentrations according to their risk of collateral resistance, based on Stiffler et al. (2015) data.

Robust ranking of drug pairs

Consider a hypothetical scenario where a drug treatment is being designed for a patient with a tumor or a bacterial infection. In selecting a drug, it is desirable to take into account not only the standard medical considerations, such as drug availability, toxicity, etc., but also the possibility that the treatment with this drug will fail due to the evolution of resistance. Therefore, it may be prudent to consider a list of drugs pairs (or higher-order combinations), ranked by the propensity of the first drug in the pair to elicit collateral resistance against the second drug in the pair. All else being equal, the drug deployed first should form a high-ranking pair with at least one other secondary drug. Then, if the treatment with the first drug fails, a second one can be deployed with a minimal risk of collateral resistance. Thus, we set out to develop a metric for ranking drug pairs according to this risk.

Clearly, any drug pair with a negative r_2 is preferable over any drug pair with a positive r_2 , since the evolution in the presence of the first drug in a pair with $r_2 < 0$ is expected to elicit collateral sensitivity against the second drug in the pair but the opposite is true for drug pairs with $r_2 > 0$. It is also clear that among two drug pairs with negative r_2 , a pair with a more negative r_2 and lower D_{22} is preferable over a pair with a less negative r_2 and higher D_{22} because evolution in the presence of the first drug in the former pair will more reliably lead to stronger collateral sensitivity against the second drug in the pair. The difficulty is in how to compare and rank two drug pairs where one pair has a more negative r_2 but higher D_{22} . Our theory shows that the chance of emergence of collateral

resistance monotonically increases with the collateral risk statistic $c = r_2/\sqrt{D_{22}}$ (see Materials and Methods). Thus, we propose to rank drug pairs by c from lowest (most negative and therefore most preferred) to highest (least negative or most positive and therefore least preferred).

To demonstrate the utility of such ranking, consider four hypothetical drug pairs with JDFEs shown in **Figure 4A**. The similarity between their shapes makes it difficult to predict *a priori* which one would have the lowest and highest probabilities of collateral resistance. Thus, we rank these JDFEs by their c statistic. To test whether this ranking is accurate with respect to the risk of collateral resistance, we simulate the evolution of a Wright-Fisher population in the presence of the first drug in each pair for 600 generations and estimate the probability that the evolved population has a positive fitness in the presence of the second drug, i.e., the probability that it becomes collaterally resistant (**Figure 4B**). We find that our *a priori* ranking corresponds perfectly to the ranking according to this probability, evidenced by the consistently higher collateral resistance risk for JDFEs with higher c (**Figure 4B**). Interestingly, the top ranked JDFE does not have the lowest expected pleiotropic effect r_2 . Nevertheless, the fact that the pleiotropic variance statistic D_{22} for this JDFE is small ensures that the risk of collateral resistance evolution is the lowest. This 1 to 1 rank correlation holds more broadly, for all 125 Gaussian JDFEs and all population genetic parameters considered in the previous section (**Figure 4C**) as well as for the empirical TEM β -lactamase JDFEs (**Figure 4–Figure Supplement 1**). Overall, we find that we can use the collateral risk statistic c to robustly rank drug pairs according to the risk of collateral resistance evolution, irrespective of the population genetic parameters.

Measuring JDFEs

So far, we assumed that the parameters of the JDFE on which the population evolves are known. In reality, they have to be estimated from data, which opens up at least two practically important questions. The first question is experimental. From what types of data can JDFEs be in principle estimated and how good are different types of data for this purpose? We can imagine, for example, that some properties of JDFEs can be estimated from genome sequencing data (*Jerison et al., 2020*) or from temporally resolved fitness trajectories (*Bakerlee et al., 2021*). Here we focus on the most direct way of estimating JDFE parameters, from the measurements of the home and non-home fitness effects of individual mutations. The experimental challenge with this approach is to sample those mutations that will most likely contribute to adaptation in the home environment (see “Discussion” for an extended discussion of this problem). Below, we propose two potential strategies for such sampling: the Luria-Delbrück (LD) method and the barcode lineage tracking (BLT) method. The second question is statistical: how many mutants need to be sampled to reliably rank drug pairs according to the risk of collateral resistance? We evaluate both proposed methods with respect to this property.

The idea behind the LD method is to expose the population to a given drug at a concentration above the minimum inhibitory concentration (MIC), so that only resistant mutants survive (*Pinheiro et al., 2021*). This selection is usually done on agar plates, so that individual resistant mutants form colonies and can be isolated. The LD method is relatively easy to implement experimentally, but it is expected to work only if the drug concentration is high enough to kill almost all non-resistant cells. In reality, resistant mutants may be selected at concentrations much lower than MIC (*Andersson and Hughes, 2014*). Furthermore, mutants selected at different drug concentrations may be genetically and functionally distinct (*Lindsey et al., 2013; Pinheiro et al., 2021*) and therefore may have statistically different pleiotropic profiles. As a result, mutants sampled with the LD method may not be most relevant for predicting collateral evolution at low drug concentrations, and other sampling methods may be required for isolating weakly beneficial mutations.

Isolating individual weakly beneficial mutations is more difficult because by the time a mutant reaches a detectable frequency in the population it has accumulated multiple additional driver and passenger mutations (*Lang et al., 2013; Nguyen Ba et al., 2019*), all of which can potentially have collateral effects. One way to isolate many single beneficial mutations from experimental

populations is by using the recently developed barcode lineage tracking (BLT) method (Levy et al., 2015; Venkataram et al., 2016). In a BLT experiment, each cell is initially tagged with a unique DNA barcode. As long as there is no recombination or other DNA exchange, any new mutation is permanently linked to one barcode. A new adaptive mutation causes the frequency of the linked barcode to grow, which can be detected by sequencing. By sampling many random mutants and genotyping them at the barcode locus, one can identify mutants from adapted lineages even if they are rare (Venkataram et al., 2016). As a result, BLT allows one to sample mutants soon after they acquire their first driver mutation, before acquiring secondary mutations.

To evaluate the quality of sampling based on the LD and BLT methods, we consider the following hypothetical experimental setup. K beneficial mutants are sampled from each home environment (with either one of the methods), and their home and non-home fitness (X_i, Y_i) are measured for each mutant $i = 1, \dots, K$. Since we are ultimately interested in ranking drug pairs by their risk of collateral resistance, we estimate the collateral risk statistic $\hat{c}$ from these fitness data for each drug pair and use $\hat{c}$ to rank them (see Materials and Methods for details). We compare such *a priori* ranking of 125 hypothetical drug pairs with Gaussian JDFEs used in previous sections with their *a posteriori* ranking based on the risk of collateral resistance observed in simulations.

Figure 5. Sampling effects on the ranking of drug pairs. Both panels show correlations between the *a priori* estimated c -rank (x-axis) of the 125 Gaussian JDFEs and their *a posteriori* rank (y-axis) based on the risk of collateral resistance observed in simulations (same data as the y-axis in Figure 4C for $NU_b = 0.46$). **A.** The c statistic is estimated using the Luria-Delbrück method (see text for details). Cutoff for sampling mutations is 0.5σ , where σ is the standard deviation of the JDFE in the home environment. See Figure 5-Figure Supplement 1 for other cutoff values. **B.** The c statistic is estimated using the barcode lineage tracking method with $N = 10^6$ and $U = 10^{-4}$ (see text and Materials and Methods for details). $P < 10^{-6}$ for all regressions.

Figure 5-Figure supplement 1. Same as Figure 5A, but with different thresholds for sampling.

To model the LD sampling method on a given JDFE, we randomly sample K mutants whose home fitness exceeds a certain cutoff. To model a BLT experiment, we simulate evolution in the home environment and randomly sample K beneficial mutants segregating at generation 250 (see Materials and Methods for details). We find that the $\hat{c}$ -ranking estimated with either LD or BLT methods captures the *a posteriori* ranking surprisingly well, even when the number of sampled mutants is as low as 10 per drug pair (Figure 5). Given that the JDFEs with adjacent ranks differ in c by a median of only 0.65%, the strong correlations shown in Figure 5 suggest that even very similar JDFEs can be differentiated with moderate sample sizes. As expected, this correlation is further improved upon increased sampling, and it is insensitive to the specific home fitness threshold that we use in the LD method (Figure 5-Figure Supplement 1). We conclude that estimating JDFE parameters is in principle feasible with a modest experimental effort, at least for the purpose of ranking drug pairs.

Discussion

We have shown that many resistance mutations against multiple drugs in *E. coli* exhibit a diversity of collateral effects. If this is true more generally, it implies that there is an unavoidable uncertainty in whether any given population would evolve collateral resistance or sensitivity, which could at least in part explain previously observed inconsistencies among experiments. We quantified the diversity of pleiotropic effects of mutations with a joint distribution of fitness effects (JDFE) and developed a population genetic theory for predicting the expected collateral outcomes of evolution and the uncertainty around these expectations. In the successional mutations regime, our theory shows that the average rate at which fitness in the non-home environment is gained or lost during adaptation to the home environment is determined by the pleiotropy statistic r_2 given by **Equation 8**. How strongly the non-home fitness in any individual population deviates from this ensemble average is determined by the pleiotropy variance statistic D_{22} given by **Equation 11**. Importantly, r_2 and D_{22} are properties of the JDFE alone, i.e., they do not depend on the parameters of any specific population. In the concurrent mutations regime, the expected rate of non-home fitness gain or loss and the associated variance are reasonably well predicted by the adjusted pleiotropy statistics r_2^* and D_{22}^* . Unlike r_2 and D_{22} , the adjusted statistics depend on the population size N and the rate of beneficial mutations U_b .

To quantitatively predict the probability of evolution of collateral drug resistance in practice would require the knowledge of both the JDFE for the focal bacterial or cancer-cell population in the presence of the specific pair of drugs and its *in vivo* population genetic parameters. Since estimating the latter parameters is very difficult, it appears unlikely that we would be able to quantitatively predict the dynamics of collateral effects, even if JDFEs were known. A more realistic application of our theory is that it allows us to rank drug pairs according to the risk of collateral resistance even when the population genetic parameters are unknown. Such robust ranking can be computed based on the collateral risk statistic $c = r_2 / \sqrt{D_{22}}$, a property of the JDFE but not of the evolving population. Drug pairs with positive values of c have a higher chance of eliciting collateral resistance than collateral sensitivity and should be avoided; drug pairs with more negative values of c have a lower risk of collateral resistance evolution than those with less negative values.

We have validated our theory *in silico*, but how well it would work *in vivo* (in the clinic) or even *in vitro* (in the lab) is as of yet unclear. A direct way to validate the theory empirically would be to estimate JDFEs for a model organism, such as *E. coli*, in a number of drug pairs, rank these pairs according to our collateral rank statistic and then test this ranking by evolving replicate populations and measuring the empirical distributions of collateral resistance/sensitivity outcomes. To the best of our knowledge, the antibiotic resistance JDFEs among genome-wide mutations have not yet been measured. One could in principle use existing gene knock-out data, such as those obtained by **Chevereau et al. (2015) (Figure 1)**, or the data from deep mutational scanning experiments, such as those obtained by **Stiffler et al. (2015) (Figure 1–Figure Supplement 1)**, to estimate JDFEs. However, these experiments estimate fitness only for certain subsets of mutations (gene knock-outs or point mutations within a single gene, respectively). Since resistance may arise via other types of mutations **Nichol et al. (2019)**, these data would give us at best an incomplete picture of actual JDFEs. Our results suggest that JDFEs can be reasonably well estimated by sampling resistance mutants at drug concentrations above MIC or by employing the barcode lineage tracking method.

Another obstacle is that, even though many researchers have experimentally evolved various microbes in the presence of drugs, most experiments have maintained too few replicate populations to accurately measure the variation in collateral outcomes of evolution. The study by **Nichol et al. (2019)**, with 60 replicates, is a notable exception. In short, a rigorous test of our theory requires new data on the shapes of whole-genome JDFEs as well as higher throughput evolution experiments.

What the most effective ways of measuring JDFEs are and whether it will be possible to measure JDFE *in vivo* are open questions. We speculate that the answers will depend on the shapes of the empirical JDFEs because some shapes may be more difficult to estimate than others. For example,

if empirical JDFEs resemble multivariate Gaussian distributions, then we can learn all relevant parameters of such JDFE by sampling a handful of random mutants and measuring their fitness in relevant environments. One can also imagine more complex JDFEs where mutations beneficial in the home environment have a dramatically different distribution of non-home fitness effects than mutations that are deleterious or neutral in the home environment. In this case, very large samples of random mutations would be necessary to correctly predict the pleiotropic outcomes of evolution, so that methods that preferentially sample beneficial mutations may be required. We have considered two such methods, which are experimentally feasible. We have shown that both of them perform extremely well on Gaussian JDFEs in the sense that as few as 10 mutants per drug pair are sufficient to produce largely correct ranking of hypothetical drug pairs. However, it may be difficult to apply these methods *in vivo*, in which case JDFEs may have to be estimated in the lab, with selection pressures reproducing those *in vivo* as accurately as possible.

Our model relies on two important simplifications. It describes the evolution of an asexual population where all resistance alleles arise from *de novo* mutations. In reality, some resistance alleles in bacteria may be transferred horizontally (Sun et al., 2019). Understanding collateral resistance evolution in the presence of horizontal gene transfer events would require incorporating JDFE into other models of evolutionary dynamics (e.g., Neher et al., 2010). Another major simplification is in the assumption that the JDFE stays constant as the population adapts. In reality the JDFE will change over time because of the depletion of the pool of adaptive mutations and because of epistasis (Good et al., 2017; Venkataram et al., 2020). How JDFEs vary among genetic backgrounds is currently unknown. In Appendix 1, we have shown that our main results hold at least in the presence of a simple form of “global” epistasis. Empirically measuring how JDFEs vary across genotypes and theoretically understanding how such variation affects the evolution of pleiotropic outcomes are important open questions.

While we were primarily motivated by the problem of evolution of collateral drug resistance and sensitivity, our theory is applicable more broadly. The shape of JDFE must play a crucial role in determining whether the population evolves towards a generalist or diversifies into multiple specialist ecotypes. Previous literature has viewed this question primarily through the lense of two alternative hypotheses: antagonistic pleiotropy and mutation accumulation (Visher and Boots, 2020). Antagonistic pleiotropy in its strictest sense means that the population is at the Pareto front with respect to the home and non-home fitness, such that any mutation beneficial in the home environment reduces the fitness in the non-home environment (Li et al., 2019). The shape of the Pareto front then determines whether selection would favor specialists or generalists (Levins, 1968; Visher and Boots, 2020). Alternatively, a population can evolve to become a home-environment specialist even in the absence of trade-offs, simply by accumulating mutations that are neutral in the home environment but deleterious in the non-home environment (Kawecki, 1994). More recently, it has been recognized that antagonistic pleiotropy and mutation accumulation are not discrete alternatives but rather extremes of a continuum of models (Bono et al., 2020; Jerison et al., 2014, 2020). The JDFE provides a mathematical way to describe this continuum. For example, strict antagonistic pleiotropy can be modeled with a JDFE with zero probability weight in the first quadrant and a bulk of probability in the fourth quadrant. A mutation accumulation scenario can be modeled with a “+”-like JDFE where all mutations beneficial in the home environment are neutral in the non-home environment (i.e., concentrated on the x -axis) and all or most mutations neutral in the home environment (i.e., those on the y -axis) are deleterious in the non-home environment. Our theory shows that in fact all JDFEs with negative r_2 lead to loss of fitness in the non-home environment and therefore can potentially promote specialization. While our theory provides this insight, further work is needed to understand how JDFEs govern adaptation to variable environments. This future theoretical work, together with empirical inquiries into the shapes of JDFEs, will not only advance our ability to predict evolution in practical situations, such as drug resistance, but it will also help us better understand the origins of ecological diversity.

Materials and Methods

Analysis of knock-out and deep mutational scanning data

Knock-out data

Chevereau et al. (2015) provide growth rate estimates for 3883 gene knock-out mutants of *E. coli* in the presence of six antibiotics. Our goal is to identify those knock-out mutations that provide resistance against one drug and are also collaterally resistant or collaterally sensitive to another drug. However, it is unclear from these original data alone which mutations have statistically significant beneficial and deleterious effects because no measurement noise estimates are provided. To address this problem, we obtained replicate wildtype growth rate measurements in the presence of antibiotics from Guillaume Chevereau and Tobias Bollenbach (available at <https://github.com/ardellsarah/JDFE-project>). In this additional data set, the wildtype *E. coli* strain is measured on average 476 times in the presence of each drug. We estimate the wildtype growth rate r_{WT} as the mean of these measurements, and we obtain the selection coefficient for all knock-out mutants as $s_i = r_i - r_{WT}$. We also obtain the noise distribution $P_{\text{noise}}(s)$ from the replicate wildtype measurements (shown in red in the diagonal panels in **Figure 1**). Modeling $P_{\text{noise}}(s)$ as normal distributions, we obtain the P -values for each mutation in the presence of each antibiotic.

We then call any knock-out mutant as resistant against a given drug if its selection coefficient in the presence of that drug exceeds a critical value $s_{\alpha}^{+} > 0$. We choose s_{α}^{+} using the Benjamini-Hochberg procedure (*Benjamini and Hochberg, 1995*) so that the false discovery rate (FDR) among the identified resistant mutants is $\alpha \approx 0.25$. We could not find an s_{α}^{+} for $\alpha \lesssim 0.25$ for trimethoprim (TMP) and chloramphenicol (CHL), i.e., there were not enough knock-out mutations with positive selection coefficients to reliably distinguish them from measurement errors.

We apply the same procedure to identify mutations that are collaterally resistant and collaterally sensitive against a second drug among all mutations that are resistant against the first drug, except we aim for $\text{FDR} \lesssim 0.10$.

Deep mutational scanning data

Stiffler et al. (2015) provide estimates of relative fitness for 4997 point mutations in the TEM-1 β -lactamase gene in the presence of cefotaxime (CTX) and four concentrations of ampicillin (AMP). We estimate the selection coefficients from the reported relative fitness values by changing the logarithm from $\log_{10}$ to natural and dividing it by six, the estimated number of generations that occurred during the 2-hour experiment. The latter is based on the fact that *Stiffler et al. (2015)* chose AMP concentrations which did not significantly alter the *E. coli* doubling time, which we assumed to be 20 minutes. We used the same number of generations for CTX.

Stiffler et al. (2015) report two replicate measurements per mutant in each concentration of AMP and one measurement per mutant in the presence of CTX. We consider CTX as the home environment and call all mutations with positive measured fitness effects as resistant against CTX. For each such mutation, we use two replicate measurements in each concentration of AMP to estimate its mean fitness effect and the 90% confidence interval around the mean, based on the normal distribution. We call any CTX resistant mutation with the entire confidence interval above (below) zero as collaterally resistant (sensitive) against AMP at that concentration. All remaining CTX resistant mutations are called collaterally neutral.

Theory

Successional mutations regime

We assume that an asexual population evolves according the Wright-Fisher model in the strong selection weak mutation (SSWM) limit (*Orr, 2000; Kryazhimskiy et al., 2009; Good and Desai, 2015*), also known as the “successional mutations” regime (*Desai and Fisher, 2007*). In this regime, the population remains monomorphic until the arrival of a new mutation that is destined to fix. The waiting time for such new mutation is assumed to be much longer than the time it takes for the mutation to fix, i.e., fixation happens almost instantaneously on this time scale, after which point the

541 population is again monomorphic. If the per genome per generation rate of beneficial mutations
 542 is U_b , their typical effect is s and the population size is N , the SSWM approximation holds when
 543 $NU_b \ll 1 / \ln(Ns)$ (**Desai and Fisher, 2007**).

544 We describe our population by a two-dimensional vector of random variables (X_t, Y_t) , where
 545 X_t and Y_t are the population's fitness (growth rate or the Malthusian parameter) in the home and
 546 non-home environments at generation t , respectively. We assume that the fitness vector of the
 547 population at the initial time point is known and is (x_0, y_0) . We are interested in characterizing the
 548 joint probability density $p(x, y, t) dx dy = \Pr \{X_t \in [x, x + dx), Y_t \in [y, y + dy)\}$.

549 We assume that all genotypes have the same JDfE $\Phi(\Delta x, \Delta y)$, i.e., there is no epistasis. In the
 550 exponential growth model, the selection coefficient of a mutation is the difference between the
 551 mutant and the ancestor growth rates in the home environment, i.e., Δx . The probability of fixation
 552 of the mutant is given by Kimura's formula, which we approximate by $2\Delta x$ for $\Delta x > 0$ and zero
 553 otherwise (**Crow and Kimura, 1972**).

554 If the total rate of mutations (per genome per generation) is U , the rate of mutations beneficial
 555 in the home environment is given by $U_b = U f_b$ where $f_b = \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \Phi(\xi, \eta)$ is the fraction
 556 of mutations beneficial in the home environment. Once such a mutation arises, its selection
 557 coefficients in the home and non-home environments are drawn from the JDfE of mutations
 558 beneficial in the home environment $\Phi_b(\Delta x, \Delta y) = \Phi(\Delta x, \Delta y) / f_b$. Then, in the SSWM limit, our
 559 population is described by a two-dimensional continuous-time continuous-space Markov chain with
 560 the transition rate from state (x, y) to state (x', y') given by

$$2NU_b Q(x', y' | x, y) = \begin{cases} 2NU_b (x' - x) \Phi_b(x' - x, y' - y) & \text{if } x' > x, \\ 0 & \text{otherwise.} \end{cases} \quad (3)$$

561 The probability distribution $p(x, y, t)$ satisfies the integro-differential forward Kolmogorov equation
 562 (**Van Kampen, 1992**)

$$\begin{aligned} & \frac{1}{NU_b} \frac{\partial p}{\partial t}(x, y, t) \\ &= 2 \int_{-\infty}^{\infty} d\eta \int_{-\infty}^{\infty} d\xi \left(p(\xi, \eta, t) Q(x, y | \xi, \eta) - p(x, y, t) Q(\xi, \eta | x, y) \right) \end{aligned} \quad (4)$$

563 with the initial condition

$$p(x, y, 0) = \delta(x - x_0) \delta(y - y_0). \quad (5)$$

564 When beneficial mutations with large effects are sufficiently rare, equation (4) can be approximated
 565 by the Fokker-Planck equation (**Van Kampen, 1992**)

$$\frac{1}{NU_b} \frac{\partial p}{\partial t} = -r_1 \frac{\partial p}{\partial x} - r_2 \frac{\partial p}{\partial y} + \frac{D_{11}}{2} \frac{\partial^2 p}{\partial x^2} + D_{12} \frac{\partial^2 p}{\partial x \partial y} + \frac{D_{22}}{2} \frac{\partial^2 p}{\partial y^2}, \quad (6)$$

566 where

$$r_1 = 2 \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \xi^2 \Phi_b(\xi, \eta), \quad (7)$$

$$r_2 = 2 \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \eta \xi \Phi_b(\xi, \eta) \quad (8)$$

567 are the expected fitness effects in the home and non-home environments for a mutation fixed in
 568 the home environment, and

$$D_{11} = 2 \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \xi^3 \Phi_b(\xi, \eta), \quad (9)$$

$$D_{12} = 2 \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \eta \xi^2 \Phi_b(\xi, \eta), \quad (10)$$

$$D_{22} = 2 \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \eta^2 \xi \Phi_b(\xi, \eta) \quad (11)$$

are the second moments of the distribution of the fitness effects of mutations fixed in the home environment. The solution to **Equation 6** with the initial condition **Equation 5** is a multi-variate normal distribution with the mean vector $\mathbf{m}(t)$ and the variance-covariance matrix $\sigma^2(t)$ given by **Equation 1** and **Equation 2**.

Concurrent mutations regime

The theory we developed so far for the successional mutations regime breaks down in the concurrent mutations regime, i.e., when multiple adaptive mutations segregate in the population simultaneously (**Desai and Fisher, 2007**). The main effect of competition between segregating adaptive lineages is that many new beneficial mutations arise in relatively low-fitness genetic backgrounds and have almost no chance of surviving competition (**Desai and Fisher, 2007; Schiffels et al., 2011; Good et al., 2012**). As a result, the fixation probability of a beneficial mutation with selective effect Δx in the home environment is no longer $2\Delta x$. Instead, beneficial mutations that provide fitness benefits below a certain threshold x_c behave as if they are effectively neutral (i.e., their fixation probability is close to zero), and most adaptation is driven by mutations with benefits above x_c , where x_c depends on the population genetic parameters N and U_b as well as the shape of the distribution of fitness effects of beneficial mutations. **Good et al. (2012)** derived equations that allow us to calculate the effective fixation probability $\pi^*(\Delta x; N, U_b)$ of a beneficial mutation with the fitness benefit Δx in the home environment in the concurrent mutation regime. Thus, to predict the average rate of non-home fitness change, we replace the SSWM fixation probability 2ξ in **Equation 8** with $\pi^*(\xi; N, U_b)$ and obtain the adjusted expected pleiotropic effect

$$r_2^*(N, U_b) = \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \eta \pi^*(\xi; N, U_b) \Phi_b(\xi, \eta). \quad (12)$$

We similarly obtain the adjusted pleiotropic variance statistic

$$D_{22}^*(N, U_b) = \int_{-\infty}^{\infty} d\eta \int_0^{\infty} d\xi \eta^2 \pi^*(\xi; N, U_b) \Phi_b(\xi, \eta), \quad (13)$$

although, as discussed in Section “The population genetics of pleiotropy”, we do not expect D_{22}^* to capture all of the variation in non-home fitness trajectories.

To calculate $\pi^*(\Delta x; N, U_b)$ for the Gaussian JDFEs shown in **Figure 2**, we first substitute equation (20) in **Good et al. (2012)** with $\beta = 2$ into equations (18), (19) in **Good et al. (2012)** and then numerically solve these equations for x_c and v using the FindRoot numerical method in Mathematica. Note that all our Gaussian JDFEs share the same mean and variance in the home environment, so we need to solve these equations only once for each pair of N and U_b values. We then substitute the obtained values of x_c and v into equations (4) and (9) in **Good et al. (2012)** and calculate π^* by a numerical integration of equation (6) in **Good et al. (2012)** in R (available at <https://github.com/ardellsarah/JDFE-project>).

Ranking of drug pairs

According to **Equation 1** and **Equation 2**, both the expected non-home fitness and its variance change linearly with time, so that at time t the mean is $Z = c\sqrt{NU_b}t$ standard deviations above y_0 (if $r_2 > 0$) or below y_0 (if $r_2 < 0$), where $c = r_2/\sqrt{D_{22}}$. In other words, if $r_2 > 0$, the bulk of the non-home fitness distribution eventually shifts above y_0 , and if $r_2 < 0$, it shifts below y_0 . All else being equal, a larger value of $|c|$ implies faster rate of this shift.

The interpretation of these observations in terms of collateral resistance/sensitivity is that adaptation in the presence of the first drug will eventually lead to collateral resistance against the second drug if $r_2 > 0$ and to collateral sensitivity if $r_2 < 0$. Furthermore, all else being equal, collateral sensitivity evolves faster and the chance of evolving collateral resistance is smaller for drug pairs with more negative c (i.e., larger $|c|$). Thus, we use c to order drug pairs from the most preferred (those with the most negative values of c) to least preferred (those with least negative or positive values of c).

613 Generation of JDFEs

614 Gaussian JDFEs

615 The JDFEs in **Figure 2** have the following parameters. Mean in the home environment: -0.05 .
616 Standard deviation in both home and non-home environments: 0.1 . Means in the non-home
617 environment: $0.08, 0.145, 0, -0.145, -0.08$ in panels A through E, respectively.

618 The JDFEs in **Figure 3** have the following parameters. Mean and standard deviation in the home
619 environment: -0.001 and 0.01 , respectively. The non-home mean varies between 0.0001 and 0.01 .
620 The non-home standard deviation varies between 0.0001 and 0.01 . The correlation between home
621 and non-home fitness varies between -0.9 and 0.9 , for a total of 125 JDFEs. All parameter values
622 and the resulting pleiotropy statistics for these JDFEs are given in the **Figure 3-source data 1**.

623 JDFEs with equal probabilities of pleiotropically beneficial and deleterious mutations

624 All JDFEs in **Figure 2-Figure Supplement 1** are mixtures of two two-dimensional uncorrelated
625 Gaussian distributions, which have the following parameters. Mean in the home environment:
626 0.4 . Standard deviation in both home and non-home environments: 0.1 . Means in the non-home
627 environment: 0.1 and -0.1 in panel A, 0.5 and -0.5 in panel B, 0.17 and -0.5 in panel C, and 0.5 and
628 -0.17 in panel D.

629 Simulations

630 We carried out two types of simulations, SSWM model simulations and full Wright-Fisher model
631 simulations.

632 Strong selection weak mutation

633 The SSWM simulations were carried out using the Gillespie algorithm (**Gillespie, 1976**), as follows.
634 We initiate the populations with home and non-home fitness values $x_0 = 0$ and $y_0 = 0$. At each
635 iteration, we draw the waiting time until the appearance of the next beneficial mutation from
636 the exponential distribution with the rate parameter NU_b and advance the time by this amount.
637 Then, we draw the selection coefficients Δx and Δy of this mutation in the home- and non-home
638 environment, respectively, from the JDFE (a multivariate normal distribution). With probability $2\Delta x$,
639 the mutation fixes in the population. If it does, the fitness of the population is updated accordingly.

640 Wright-Fisher model

641 We simulate evolution in the home environment according to the Wright-Fisher model with pop-
642 ulation size N as follows. We initiate the whole population with a single genotype with fitness
643 $x_0 = 0$ and $y_0 = 0$ in the home and non-home environments. Suppose that at generation t , there
644 are $K(t)$ genotypes, such that genotype i has home- and non-home fitness X_i and Y_i , respectively,
645 and it is present at frequency $f_i(t) > 0$ in the population. We generate the genotype frequencies
646 at generation $t + 1$ in three steps. In the reproduction step, we draw random numbers $B'_i(t + 1)$,
647 $i = 1, \dots, K(t)$ from the multinomial distribution with the number of trials N and success probabilities
648 $p_i(t) = f_i(t) + f_i(t) \left(X_i(t) - \bar{X}(t) \right)$, where $\bar{X}(t) = \sum_{i=1}^{K(t)} X_i(t) f_i(t)$ is the mean fitness of the population in
649 the home environment at generation t . In the mutation step, we draw a random number M of new
650 mutants from the Poisson distribution with parameter NU , where U is the total per individual per
651 generation mutation rate. We randomly determine the “parent” genotypes in which each mutation
652 occurs and turn the appropriate numbers of parent individuals into new mutants. We assume
653 that each new mutation creates a new genotype and has fitness effects Δx and Δy in the home
654 and non-home environments. Δx and Δy are drawn randomly from the JDFE $\Phi(\Delta x, \Delta y)$. We obtain
655 each mutants fitness by adding these values to the parent genotype’s home and non-home fitness
656 values. In the final step, all genotypes that are represented by zero individuals are removed and
657 we are left with $K(t + 1)$ genotypes with $B_i(t + 1) > 0$, $i = 1, \dots, K(t + 1)$ individuals. Then we set
658 $f_i(t + 1) = B_i(t + 1)/N$.

Sampling beneficial mutants from JDfEs and estimating the collateral risk statistic

We model the LD sampling method by randomly drawing mutants from the JDfE until the desired number K of mutants whose home fitness exceeds the focal threshold are sampled. We estimate the c statistic from the pairs of home and non-home fitness effects X_i and Y_i of these $i = 1, \dots, K$ sampled mutants. To do so, we first estimate r_2 and D_{22} as $\hat{r}_2 = 1/K \sum_{i=1}^K X_i Y_i$ and $\hat{D}_{22} = 1/K \sum_{i=1}^K X_i^2 Y_i^2$. We then calculate $\hat{c} = \hat{r}_2 / \sqrt{\hat{D}_{22}}$.

For the BLT sampling method, we simulate the Wright-Fisher model as described above for $N = 10^6$ and $U = 10^{-4}$ for 250 generations. At generation 250, we randomly sample existing beneficial mutants proportional to their frequency in the population without replacement (i.e., the same beneficial mutation is sampled at most once). Sampling more than ~ 50 distinct beneficial mutants from a single population becomes difficult because there may simply be not enough such mutants or some of them may be at very low frequencies. Therefore, if the desired number of mutants to sample exceeds 50, we run multiple replicate simulations and sample a maximum of 100 distinct beneficial mutants per replicate until the desired number of mutants is reached. We then estimate the c statistics as with the LD method.

Code availability

All scripts are available at <https://github.com/ardellsarah/JDFE-project>.

Acknowledgements

We thank Shea Summers and Flora Tang for help and input at the initial stages of the project and Kryazhimskiy and Meyer labs for feedback. We thank Tobias Bollenbach and Guillaume Chevereau for providing wildtype growth rate measurement data. This work was supported by the BWF Career Award at Scientific Interface (Grant 1010719.01), the Alfred P. Sloan Foundation (Grant FG-2017-9227), the Hellman Foundation and NIH (Grants 1R01GM137112 and 1T32GM133351-01).

References

- Aggeli D**, Li Y, Sherlock G. Changes in the distribution of fitness effects and adaptive mutational spectra following a single first step towards adaptation. *Nature Communications*. 2021; 12(1):1–14.
- Andersson DI**, Hughes D. Microbiological effects of sublethal levels of antibiotics. *Nature Reviews Microbiology*. 2014; 12(7):465–478.
- Bakerlee CW**, Phillips AM, Ba ANN, Desai MM. Dynamics and variability in the pleiotropic effects of adaptation in laboratory budding yeast populations. *bioRxiv*. 2021; <https://doi.org/10.1101/2021.06.24.449852>.
- Barbosa C**, Römhild R, Rosenstiel P, Schulenburg H. Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen *Pseudomonas aeruginosa*. *Elife*. 2019; 8:e51481.
- Barbosa C**, Trebosc V, Kemmer C, Rosenstiel P, Beardmore R, Schulenburg H, Jansen G. Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effects. *Molecular biology and evolution*. 2017; 34(9):2229–2244.
- Barton N**. Pleiotropic models of quantitative variation. *Genetics*. 1990; 124(3):773–782.
- Batra A**, Roemhild R, Rousseau E, Franzenburg S, Niemann S, Schulenburg H. High potency of sequential therapy with only beta-lactam antibiotics. *Elife*. 2021; 10:e68876.
- Benjamini Y**, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal statistical society: series B (Methodological)*. 1995; 57(1):289–300.
- Bergstrom CT**, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. *Proceedings of the National Academy of Sciences*. 2004; 101(36):13285–13290.
- Blundell JR**, Schwartz K, Francois D, Fisher DS, Sherlock G, Levy SF. The dynamics of adaptive genetic diversity during the early stages of clonal evolution. *Nature ecology & evolution*. 2019; 3(2):293–301.
- Bono LM**, Draghi JA, Turner PE. Evolvability costs of niche expansion. *Trends in Genetics*. 2020; 36(1):14–23.
- Bono LM**, Smith Jr LB, Pfennig DW, Burch CL. The emergence of performance trade-offs during local adaptation: insights from experimental evolution. *Molecular ecology*. 2017; 26(7):1720–1733.
- Card KJ**, Thomas MD, Graves JL, Barrick JE, Lenski RE. Genomic evolution of antibiotic resistance is contingent on genetic background following a long-term experiment with *Escherichia coli*. *Proceedings of the National Academy of Sciences*. 2021; 118(5).
- Chevereau G**, Dravecká M, Batur T, Guvenek A, Ayhan DH, Toprak E, Bollenbach T. Quantifying the determinants of evolutionary dynamics leading to drug resistance. *PLoS Biology*. 2015; 13(11):e1002299.
- Chou HH**, Chiu HC, Delaney NF, Segrè D, Marx CJ. Diminishing returns epistasis among beneficial mutations decelerates adaptation. *Science*. 2011; 332(6034):1190–1192.
- Connallon T**, Clark AG. The distribution of fitness effects in an uncertain world. *Evolution*. 2015; 69(6):1610–1618.
- Crow JF**, Kimura M. An introduction to population genetics theory. Harper & Row Ltd; 1972.
- Das SG**, Direito SO, Waclaw B, Allen RJ, Krug J. Predictable properties of fitness landscapes induced by adaptational tradeoffs. *eLife*. 2020; 9:e55155.
- Desai MM**, Fisher DS. Beneficial mutation–selection balance and the effect of linkage on positive selection. *Genetics*. 2007; 176(3):1759–1798.
- Eyre-Walker A**, Keightley PD. The distribution of fitness effects of new mutations. *Nature Reviews Genetics*. 2007; 8(8):610–618.
- Gillespie DT**. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. *Journal of computational physics*. 1976; 22(4):403–434.
- Gjini E**, Wood KB. Price equation captures the role of drug interactions and collateral effects in the evolution of multidrug resistance. *Elife*. 2021; 10:e64851.
- Good BH**, Desai MM. The impact of macroscopic epistasis on long-term evolutionary dynamics. *Genetics*. 2015; 199(1):177–190.

728 **Good BH**, McDonald MJ, Barrick JE, Lenski RE, Desai MM. The dynamics of molecular evolution over 60,000
729 generations. *Nature*. 2017; 551(7678):45–50.

730 **Good BH**, Rouzine IM, Balick DJ, Hallatschek O, Desai MM. Distribution of fixed beneficial mutations and
731 the rate of adaptation in asexual populations. *Proceedings of the National Academy of Sciences*. 2012;
732 109(13):4950–4955.

733 **Harmand N**, Gallet R, Jabbour-Zahab R, Martin G, Lenormand T. Fisher’s geometrical model and the mutational
734 patterns of antibiotic resistance across dose gradients. *Evolution*. 2017; 71(1):23–37.

735 **Hernando-Amado S**, Sanz-García F, Martínez JL. Rapid and robust evolution of collateral sensitivity in *Pseu-*
736 *domonas aeruginosa* antibiotic-resistant mutants. *Science advances*. 2020; 6(32):eaba5493.

737 **Husain K**, Murugan A. Physical constraints on epistasis. *Molecular Biology and Evolution*. 2020; 37(10):2865–
738 2874.

739 **Imamovic L**, Sommer MO. Use of collateral sensitivity networks to design drug cycling protocols that avoid
740 resistance development. *Science translational medicine*. 2013; 5(204):204ra132.

741 **Jahn LJ**, Simon D, Jensen M, Bradshaw C, Ellabaan MMH, Sommer MOA. Compatibility of evolutionary responses
742 to constituent antibiotics drive resistance evolution to drug pairs. *Molecular biology and evolution*. 2021;
743 38(5):2057–2069.

744 **Jensen P**, Holm B, Sorensen M, Christensen I, Sehested M. In vitro cross-resistance and collateral sensitivity in
745 seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere,
746 taxol, topotecan and gemcitabine. *British journal of cancer*. 1997; 75(6):869–877.

747 **Jerison ER**, Kryazhimskiy S, Desai MM. Pleiotropic consequences of adaptation across gradations of environ-
748 mental stress in budding yeast. *arXiv:14097839*. 2014; <https://arxiv.org/abs/1409.7839>.

749 **Jerison ER**, Nguyen Ba AN, Desai MM, Kryazhimskiy S. Chance and necessity in the pleiotropic consequences of
750 adaptation for budding yeast. *Nature Ecology & Evolution*. 2020; 4(4):601–611.

751 **Johnson MS**, Martsul A, Kryazhimskiy S, Desai MM. Higher-fitness yeast genotypes are less robust to deleterious
752 mutations. *Science*. 2019; 366(6464):490–493.

753 **Johnson T**, Barton N. Theoretical models of selection and mutation on quantitative traits. *Philosophical*
754 *Transactions of the Royal Society B: Biological Sciences*. 2005; 360(1459):1411–1425.

755 **Jones AG**, Arnold SJ, Bürger R. Stability of the G-matrix in a population experiencing pleiotropic mutation,
756 stabilizing selection, and genetic drift. *Evolution*. 2003; 57(8):1747–1760.

757 **Kavanaugh LG**, Flanagan JN, Steck TR. Reciprocal antibiotic collateral sensitivity in *Burkholderia multivorans*.
758 *International journal of antimicrobial agents*. 2020; 56(1):105994.

759 **Kawecki TJ**. Accumulation of deleterious mutations and the evolutionary cost of being a generalist. *The*
760 *American Naturalist*. 1994; 144(5):833–838.

761 **Khan AI**, Dinh DM, Schneider D, Lenski RE, Cooper TF. Negative epistasis between beneficial mutations in an
762 evolving bacterial population. *Science*. 2011; 332(6034):1193–1196.

763 **Kim S**, Lieberman TD, Kishony R. Alternating antibiotic treatments constrain evolutionary paths to multidrug
764 resistance. *Proceedings of the National Academy of Sciences*. 2014; 111(40):14494–14499.

765 **Kimura M**. On the probability of fixation of mutant genes in a population. *Genetics*. 1962; 47(6):713.

766 **King JL**. The role of mutation in evolution. In: *Proceedings of the Sixth Berkeley Symposium on Mathematical*
767 *Statistics and Probability*, vol. 5 University of California Press Berkeley; 1972. p. 69–100.

768 **Kryazhimskiy S**, Rice DP, Jerison ER, Desai MM. Global epistasis makes adaptation predictable despite sequence-
769 level stochasticity. *Science*. 2014; 344(6191):1519–1522.

770 **Kryazhimskiy S**, Tkačik G, Plotkin JB. The dynamics of adaptation on correlated fitness landscapes. *Proceedings*
771 *of the National Academy of Sciences*. 2009; 106(44):18638–18643.

772 **Laborda P**, Martínez JL, Hernando-Amado S. Convergent phenotypic evolution towards fosfomycin collateral
773 sensitivity of *Pseudomonas aeruginosa* antibiotic-resistant mutants. *Microbial Biotechnology*. 2021; .

774 **Lande R**, Arnold SJ. The measurement of selection on correlated characters. *Evolution*. 1983; 37:1210–1226.

775 **Lang GI**, Rice DP, Hickman MJ, Sodergren E, Weinstock GM, Botstein D, Desai MM. Pervasive genetic hitchhiking
776 and clonal interference in forty evolving yeast populations. *Nature*. 2013; 500(7464):571–574.

777 **Lázár V**, Martins A, Spohn R, Daruka L, Grézal G, Fekete G, Számel M, Jangir PK, Kintsés B, Csörgő B, et al.
778 Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. *Nature microbi-*
779 *ology*. 2018; 3(6):718–731.

780 **Lázár V**, Nagy I, Spohn R, Csörgő B, Györkei Á, Nyerges Á, Horváth B, Vörös A, Busa-Fekete R, Hrtyan M, et al.
781 Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network.
782 *Nature communications*. 2014; 5(1):1–12.

783 **Lázár V**, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgő B, et al.
784 Bacterial evolution of antibiotic hypersensitivity. *Molecular systems biology*. 2013; 9(1):700.

785 **Levins R**. *Evolution in changing environments*. Princeton University Press; 1968.

786 **Levy SF**, Blundell JR, Venkataram S, Petrov DA, Fisher DS, Sherlock G. Quantitative evolutionary dynamics using
787 high-resolution lineage tracking. *Nature*. 2015; 519(7542):181–186.

788 **Li Y**, Petrov DA, Sherlock G. Single nucleotide mapping of trait space reveals Pareto fronts that constrain
789 adaptation. *Nature ecology & evolution*. 2019; 3:1539–51.

790 **Lindsey HA**, Gallie J, Taylor S, Kerr B. Evolutionary rescue from extinction is contingent on a lower rate of
791 environmental change. *Nature*. 2013; 494(7438):463–467.

792 **Lukačičinová M**, Fernando B, Bollenbach T. Highly parallel lab evolution reveals that epistasis can curb the
793 evolution of antibiotic resistance. *Nature communications*. 2020; 11(1):1–14.

794 **MacLean RC**, Buckling A. The distribution of fitness effects of beneficial mutations in *Pseudomonas aeruginosa*.
795 *PLoS Genet*. 2009; 5(3):e1000406.

796 **Maltas J**, McNally DM, Wood KB. Evolution in alternating environments with tunable interlandscape correlations.
797 *Evolution*. 2021; 75(1):10–24.

798 **Maltas J**, Wood KB. Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit
799 antibiotic resistance. *PLoS Biology*. 2019; 17(10):e3000515.

800 **Martin G**, Lenormand T. The distribution of beneficial and fixed mutation fitness effects close to an optimum.
801 *Genetics*. 2008; 179(2):907–916.

802 **Martin G**, Lenormand T. The fitness effect of mutations across environments: Fisher's geometrical model with
803 multiple optima. *Evolution*. 2015; 69(6):1433–1447.

804 **Mira PM**, Meza JC, Nandipati A, Barlow M. Adaptive landscapes of resistance genes change as antibiotic
805 concentrations change. *Molecular biology and evolution*. 2015; 32(10):2707–2715.

806 **Munck C**, Gumpert HK, Wallin AIN, Wang HH, Sommer MO. Prediction of resistance development against
807 drug combinations by collateral responses to component drugs. *Science translational medicine*. 2014;
808 6(262):262ra156–262ra156.

809 **Neher RA**, Shraiman BI, Fisher DS. Rate of adaptation in large sexual populations. *Genetics*. 2010; 184(2):467–
810 481.

811 **Nguyen Ba AN**, Cvijović I, Echenique JIR, Lawrence KR, Rego-Costa A, Liu X, Levy SF, Desai MM. High-resolution
812 lineage tracking reveals travelling wave of adaptation in laboratory yeast. *Nature*. 2019; 575(7783):494–499.

813 **Nichol D**, Rutter J, Bryant C, Hujer AM, Lek S, Adams MD, Jeavons P, Anderson AR, Bonomo RA, Scott JG. Antibiotic
814 collateral sensitivity is contingent on the repeatability of evolution. *Nature communications*. 2019; 10(1):1–10.

815 **Ohta T**. Very slightly deleterious mutations and the molecular clock. *Journal of Molecular Evolution*. 1987;
816 26(1-2):1–6.

817 **Orr HA**. The rate of adaptation in asexuals. *Genetics*. 2000; 155(2):961–968.

818 **Orr HA**. The distribution of fitness effects among beneficial mutations. *Genetics*. 2003; 163(4):1519–1526.

819 **Oz T**, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, Ozan VB, Senturk GH, Cokol M, Yeh P, et al.
820 Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance
821 evolution. *Molecular biology and evolution*. 2014; 31(9):2387–2401.

822 **Paaby AB**, Rockman MV. The many faces of pleiotropy. *Trends in genetics*. 2013; 29(2):66–73.

823 **Pál C**, Papp B, Lázár V. Collateral sensitivity of antibiotic-resistant microbes. *Trends in microbiology*. 2015;
824 23(7):401–407.

825 **Pinheiro F**, Warsi O, Andersson DI, Lässig M. Metabolic fitness landscapes predict the evolution of antibiotic
826 resistance. *Nature Ecology & Evolution*. 2021; p. 1–11.

827 **Pluchino KM**, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy
828 against cancer multidrug resistance. *Drug Resistance Updates*. 2012; 15(1-2):98–105.

829 **Qian W**, Ma D, Xiao C, Wang Z, Zhang J. The genomic landscape and evolutionary resolution of antagonistic
830 pleiotropy in yeast. *Cell reports*. 2012; 2(5):1399–1410.

831 **Reddy G**, Desai MM. Global epistasis emerges from a generic model of a complex trait. *Elife*. 2021; 10:e64740.

832 **Rees K**, Bataillon T. Distribution of fitness effects among beneficial mutations before selection in experimental
833 populations of bacteria. *Nature Genetics*. 2006; 38(4):484–488.

834 **Roemhild R**, Linkevicius M, Andersson DI. Molecular mechanisms of collateral sensitivity to the antibiotic
835 nitrofurantoin. *PLoS Biology*. 2020; 18(1):e3000612.

836 **Roff DA**, Fairbairn D. The evolution of trade-offs: where are we? *Journal of evolutionary biology*. 2007;
837 20(2):433–447.

838 **Rose MR**. Antagonistic pleiotropy, dominance, and genetic variation. *Heredity*. 1982; 48(1):63–78.

839 **Sanz-García F**, Sánchez MB, Hernando-Amado S, Martínez JL. Evolutionary landscapes of *Pseudomonas*
840 *aeruginosa* towards ribosome-targeting antibiotic resistance depend on selection strength. *International*
841 *journal of antimicrobial agents*. 2020; 55(6):105965.

842 **Schenk MF**, Witte S, Salverda ML, Koopmanschap B, Krug J, de Visser JAG. Role of pleiotropy during adaptation
843 of TEM-1 β -lactamase to two novel antibiotics. *Evolutionary applications*. 2015; 8(3):248–260.

844 **Schiffels S**, Szöllősi GJ, Mustonen V, Lässig M. Emergent neutrality in adaptive asexual evolution. *Genetics*. 2011;
845 189(4):1361–1375.

846 **Shoval O**, Sheftel H, Shinar G, Hart Y, Ramote O, Mayo A, Dekel E, Kavanagh K, Alon U. Evolutionary trade-offs,
847 Pareto optimality, and the geometry of phenotype space. *Science*. 2012; 336(6085):1157–1160.

848 **Slatkin M**, Frank SA. The quantitative genetic consequences of pleiotropy under stabilizing and directional
849 selection. *Genetics*. 1990; 125(1):207–213.

850 **Stiffler MA**, Hekstra DR, Ranganathan R. Evolvability as a function of purifying selection in TEM-1 β -lactamase.
851 *Cell*. 2015; 160(5):882–892.

852 **Sun D**, Jeannot K, Xiao Y, Knapp CW. Horizontal gene transfer mediated bacterial antibiotic resistance. *Frontiers*
853 *in microbiology*. 2019; 10:1933.

854 **Tikhonov M**, Kachru S, Fisher DS. A model for the interplay between plastic tradeoffs and evolution in changing
855 environments. *Proceedings of the National Academy of Sciences*. 2020; 117(16):8934–8940.

856 **Van Kampen NG**. *Stochastic processes in physics and chemistry*, vol. 1. Elsevier; 1992.

857 **Van Opijnen T**, Bodi KL, Camilli A. Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction
858 studies in microorganisms. *Nature methods*. 2009; 6(10):767–772.

859 **Venkataram S**, Dunn B, Li Y, Agarwala A, Chang J, Ebel ER, Geiler-Samerotte K, Hérissant L, Blundell JR, Levy SF,
860 et al. Development of a comprehensive genotype-to-fitness map of adaptation-driving mutations in yeast.
861 *Cell*. 2016; 166(6):1585–1596.

862 **Venkataram S**, Monasky R, Sikaroodi SH, Kryazhimskiy S, Kaçar B. Evolutionary stalling and a limit on the power
863 of natural selection to improve a cellular module. *Proceedings of the National Academy of Sciences*. 2020;
864 117(31):18582–18590.

- 865 **Visher E**, Boots M. The problem of mediocre generalists: population genetics and eco-evolutionary perspectives
866 on host breadth evolution in pathogens. *Proceedings of the Royal Society B*. 2020; 287(1933):20201230.
- 867 **Wagner GP**, Zhang J. The pleiotropic structure of the genotype–phenotype map: the evolvability of complex
868 organisms. *Nature Reviews Genetics*. 2011; 12(3):204–213.
- 869 **Wang S**, Dai L. Evolving generalists in switching rugged landscapes. *PLoS Comput Biology*. 2019;
870 15(10):e1007320.
- 871 **Wang Y**, Arenas CD, Stoebe DM, Flynn K, Knapp E, Dillon MM, Wünsche A, Hatcher PJ, Moore FBG, Cooper VS,
872 et al. Benefit of transferred mutations is better predicted by the fitness of recipients than by their ecological
873 or genetic relatedness. *Proceedings of the National Academy of Sciences*. 2016; 113(18):5047–5052.
- 874 **Wiser MJ**, Ribeck N, Lenski RE. Long-term dynamics of adaptation in asexual populations. *Science*. 2013;
875 342(6164):1364–1367.

JDFE with global epistasis

Results in the main text were derived under the assumption that all genotypes have the same JDFE, i.e., in the absence of epistasis. In reality, JDFEs probably vary from one genotype to another, but how they vary is not yet well characterized. Recent studies have found that the fitness effects of many mutations available to a genotype in a given environment depend primarily on the fitness of that genotype in that environment (*Khan et al., 2011; Chou et al., 2011; Wiser et al., 2013; Kryazhimskiy et al., 2014; Johnson et al., 2019; Wang et al., 2016; Aggeli et al., 2021; Lukačšínová et al., 2020*). This dependence is sometimes referred to as global or fitness-dependent epistasis (*Kryazhimskiy et al., 2009, 2014; Reddy and Desai, 2021; Husain and Murugan, 2020*). Here, we ask whether our main results would hold if the pathogen population evolves on a JDFE with global epistasis.

Global epistasis can be modeled in our framework by assuming that the JDFE Φ_g of genotype g depends only the fitness of this genotype in the home and non-home environments, $x(g), y(g)$, i.e. $\Phi_g(\Delta x, \Delta y) = \Phi_{x(g), y(g)}(\Delta x, \Delta y)$, which is a two-dimensional extension of the model considered by *Kryazhimskiy et al. (2009)*. Thus, in the SSWM regime, the population can still be fully described by its current pair of fitness values in the home and non-home environments (X, Y) . The dynamics of the probability density $p(x, y, t)$ are governed by the same Kolmogorov equation as in the non-epistatic case, which can still be approximated by a diffusion equation **Equation 6**. However, while in the non-epistatic case the drift and diffusion coefficients of this equation, r_1, r_2, D_{11}, D_{12} and D_{22} are constants, in the presence of global epistasis, they become functions of x and y . Although this equation cannot be solved analytically in the general case, it can be solved numerically, provided that the functions $r_1(x, y), r_2(x, y), D_{11}(x, y), D_{12}(x, y)$ and $D_{22}(x, y)$ are known. Thus, in principle, our theory can predict the trajectories of non-home fitness in the presence of global epistasis.

To explore the implications of global epistasis for collateral drug resistance evolution, we consider the simplest scenario where the functional form of global epistasis (i.e., how $\Phi_{x,y}$ depends on x and y) is the same across different drugs. In this case, we would expect that the ranking of drug pairs according to the risk of collateral resistance would be the same for all genotypes. In particular, the drug pair whose risk of collateral resistance risk is the lowest for the wildtype should also be the pair with the lowest risk for the evolved genotypes.

Appendix 1 Figure 1. Evolution on JDFEs with global epistasis and the risk of collateral resistance. **A.** Gaussian JDFE with global epistasis as it changes along the expected evolutionary trajectory shown in panel B. Parameters of the initial JDFE at $x = y = 0$ are the same as for the rank 1 JDFE in **Figure 4A**; $\gamma_h = \gamma_{nh} = 0.5$. **B.** Home and non-home fitness trajectories for the JDFE with global epistasis shown in panel A. Thick lines show the mean, ribbons show ± 1 standard deviation estimated from 500 replicate simulations. Population size $N = 10^4$, mutation rate $U = 10^{-4}$. Dashed vertical lines indicate the time points at which the JDFE snapshots in panel A are shown. **C.** Probability of collateral resistance over time for four Gaussian JDFEs with global epistasis. Parameters of the initial JDFEs at $x = y = 0$ are the same as for the four JDFE in **Figure 4A**, and $\gamma_h = \gamma_{nh} = 0.5$ for all of them. $N = 10^4$, mutation rate $U = 10^{-4}$, 1500 replicate simulation runs per JDFE. Colored numbers indicate the predicted c -rank of the initial JDFEs (same as in **Figure 4A**).

To test this prediction, we model resistance evolution on Gaussian JDFEs whose mean vector and the correlation coefficient are fixed while the standard deviations $\sigma_h(x)$ and $\sigma_{nh}(y)$ in the home and non-home environments decrease linearly with the fitness in the respective environment, $\sigma_h(x) = \max\{0, \sigma_{h,0} - \gamma_h x\}$ and $\sigma_{nh}(y) = \max\{0, \sigma_{nh,0} - \gamma_{nh} y\}$.

Appendix 1 **Figure 1A** shows how one such JDFE changes along the expected evolutionary trajectory. The corresponding expected home and non-home fitness trajectories and their variance are shown in Appendix 1 **Figure 1B**. Appendix 1 **Figure 1C** shows how the probability (risk) of collateral resistance changes over time on four different JDFEs with global epistasis. For the ancestral strain (whose fitness we set by convention to $x = y = 0$), these four JDFEs are identical to those shown in **Figure 4A**; as the populations evolve, JDFEs change as specified above with $\gamma_h = \gamma_{nh} = 0.5$. As expected, the ranking of these epistatic JDFEs according to the risk of collateral resistance stays constant over time and can be predicted from estimates of the c parameters for the ancestral strain.

Figure 1-Figure supplement 1. Fitness effects of single point mutations in the TEM-1 β -lactamase gene in *E. coli* in the presence of cefotaxime and ampicillin. Data from *Stiffler et al. (2015)*. Panels show data for different concentrations of ampicillin, as indicated. Fitness is measured as the change in the log ratio of the mutant to wildtype frequency during growth in the presence of the drug. Cefotaxime (CTX) is chosen as the home environment (see *Materials and Methods* for details). Each point represents a single point mutation and is colored by its (collateral) fitness effect in the presence of ampicillin, as indicated in the legend. The numbers of mutations with positive fitness in the presence of cefotaxime with different collateral effects are shown in the lower right corner of each panel.

Figure 2-Figure supplement 1. Same as Figure 2, but for JDFEs with equal probability weights in the first and fourth quadrants. See *Materials and Methods* for details.

Figure 5—Figure supplement 1. Same as **Figure 5A**, but with different thresholds for sampling mutations, as indicated above each panel (σ is the standard deviation of the JDPE in the home environment). See Materials and Methods for details. $P < 10^{-6}$ for all regressions.